P
Paradigm Diagnostics
Private molecular information corporation established to bring cutting-edge diagnostics to cancer patients and industry
About Paradigm Diagnostics
Paradigm Diagnostics, now part of Exact Sciences, specializes in advanced cancer diagnostics through its flagship product, PCDx. This comprehensive next-generation sequencing test assesses 90 FDA-approved therapeutic associations in cancer, including clinical trials by testing mutations, copy number variations, tumor mutation burden, and protein expression. The company operates in the healthcare sector, specifically targeting oncologists and healthcare providers who require rapid and accurate diagnostic results to inform treatment decisions. Paradigm Diagnostics' business model revolves around providing timely and precise diagnostic services, generating revenue through the sale of its PCDx tests. The company promises a clinically relevant turnaround time of 3-5 business days from sample receipt to reporting, ensuring that healthcare providers receive actionable genomic insights swiftly. The process involves multiple steps, including sample receipt, DNA extraction, sequencing, and clinical interpretation, all designed to deliver accurate results even from the smallest specimens.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2012
- Headquarters
- Phoenix, United States
- Open positions
- None listed
- Dealroom signal
- 55.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, DNA, Genetics and genomics, Spinout, Genome Engineering, Biotech and Pharma, proteomics, DT and LS, science-based
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Mar 2020 | $0 | — | Exact Sciences | ↗ |
| SERIES B✓Equity / VC | May 2019 | $15M | $60M | BlueStone Venture Partners · New Science Ventures · Gore Range Capital · Prairie Ventures | — |
Growth signals
Latest recorded traffic for Paradigm Diagnostics is 390 monthly website visits, down 70% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
New Science Ventures
Mesa Verde Venture Partners
BlueStone Venture Partners
Gore Range Capital
Prairie Ventures
Other known investors4 additional known investors
Exact Sciences
International Genomics Consortium
University of Michigan
SeedFolio
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Paradigm Diagnostics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Paradigm Diagnostics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.